Harel Insurance backs Omnix Medical
Jerusalem-based biopharmaceutical company Omnix Medical has raised $25 million in a Series C funding round co-led by Harel Insurance & Finance and the EIC Fund.
Founded in 2015, Omnix Medical is a developer of anti-infectives for the treatment of life-threatening infections. This financing will enable Omnix to complete Phase II proof-of-concept studies for its lead compound, OMN6. The studies will focus on treating life-threatening infections caused by Gram-negative bacteria, particularly Acinetobacter baumannii, including strains resistant to last-line treatments such as carbapenems and colistin. The funding will also support regulatory activities, manufacturing scale-up, and the advancement of Omnix’s broader pipeline of engineered antimicrobial peptides.
“The rise of antibiotic-resistant infections is not just a medical crisis – it’s a societal one. At Harel, we are dedicated to supporting innovation and biotech, and we believe that companies like Omnix are essential to ensuring the development of effective treatments that protect lives and promote long-term wellbeing.” – Tomer Goldberg, Vice President, Managing Director Harel Technology Investments at Harel Insurance & Finance.
“With the co-leadership of Harel Insurance & Finance and the EIC Fund, and the strong continued support of our existing shareholders, we now have the resources to complete Phase II proof-of-concept studies of OMN6, strengthen our regulatory and manufacturing capabilities, and advance our entire pipeline. We are proud to have both the backing of new investors and the renewed trust of our long-standing shareholders. Together, they reflect the confidence in Omnix’s mission to deliver truly novel anti-infective solutions.” – Dr. Moshik Cohen-Kutner, CEO of Omnix Medical.
“OMN6’s unique selectivity for bacterial membranes, its rapid pore-forming action, and its engineered stability are fundamentally different approaches to fighting resistant pathogens. These qualities not only enable fast and effective treatment but also significantly minimize the likelihood of resistance development. With this funding, we are positioned to demonstrate OMN6’s potential to transform the treatment of multidrug-resistant infections.” – Dr. Niv Bachnoff, Chief Scientific Officer.
